Compare SXI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXI | CRNX |
|---|---|---|
| Founded | 1955 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | SXI | CRNX |
|---|---|---|
| Price | $305.34 | $83.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $289.67 | $76.75 |
| AVG Volume (30 Days) | 230.9K | ★ 6.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.54% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.98 | N/A |
| Revenue | ★ $604,535,000.00 | $1,039,000.00 |
| Revenue This Year | $14.87 | $720.10 |
| Revenue Next Year | $6.07 | $184.67 |
| P/E Ratio | $43.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $158.63 | $25.83 |
| 52 Week High | $363.89 | $84.00 |
| Indicator | SXI | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 92.96 |
| Support Level | $300.49 | $40.74 |
| Resistance Level | $363.89 | N/A |
| Average True Range (ATR) | 12.63 | 0.66 |
| MACD | -3.92 | 1.48 |
| Stochastic Oscillator | 18.15 | 99.75 |
Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.